LOGO
LOGO

Can Biodesix Sustain Its Growth Momentum In 2026?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
lungs 03022026 lt

Biodesix Inc. (BDSX), a diagnostic solutions company that achieved accelerating growth last year, is preparing to capitalize on that momentum in 2026.

The company's diagnostic tests are designed to help healthcare providers meaningfully improve lung disease diagnosis, treatment, and monitoring, as well as lower the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. It currently offers two tests that assess the risk of cancer in lung nodules and three tests that provide treatment guidance after a lung cancer diagnosis.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.

RELATED NEWS